Advertisement
YOU ARE HERE: LAT HomeCollectionsWomen S Health Initiative
IN THE NEWS

Women S Health Initiative

SCIENCE
July 10, 2002 | ROSIE MESTEL, TIMES STAFF WRITER
Three years ahead of schedule, scientists have unexpectedly halted a critical clinical trial testing the effects of hormone replacement therapy on women after menopause because of a slight but significant increase in the risk of breast cancer, heart attacks, blood clots and strokes. The trial, which tracked 16,608 women taking either the hormones estrogen and progestin or a placebo for five years, was brought to an end after a review in late May made it clear that the risks of the hormone regimen outweighed the benefits.
Advertisement
NEWS
October 19, 2010
Estrogen-plus-progestin hormone replacement therapy increases the risk of breast cancer in postmenopausal women. Now a longer-term study of the problem shows the higher risk of breast cancer continues among women who took hormones but stopped, that the cancer in these women may be more advanced and that the likelihood of dying of breast cancer is increased. The link between hormone therapy and breast cancer was confirmed with the conclusion of the Women's Health Initiative study in 2005, based on about 5 1/2 years of data.
NEWS
August 5, 2010
Far fewer women take hormone replacement therapy than did a decade ago, but the drugs are a mixed bag of risks and benefits, as studies occasionally point out. For women who are especially concerned about colon cancer, hormone therapy might be a good idea. A study has found that using hormone replacement therapy for any length of time cut the risk of distal colon cancer in half. The distal part of the colon is closest to the rectum. The longer women took hormone therapy, the greater the reduced risk.
NEWS
December 9, 2010 | By Shari Roan, Los Angeles Times
Estrogen-only hormone replacement therapy may benefit younger postmenopausal women who do not have a uterus, a Canadian researcher said Thursday at the annual meeting of the San Antonio Breast Cancer Symposium. Dr. Joseph Ragaz, an oncologist at the University of British Columbia, presented a re-analysis of the Women's Health Initiative -- which originally concluded that both long-term estrogen-only and estrogen-plus-progestin hormone replacement were too risky for most women.
NEWS
November 4, 2011 | By Shari Roan, Los Angeles Times / For the Booster Shots blog
A significant rise in hip fractures among women is one result of the decade-long slide in the popularity of hormone replacement therapy, researchers report in a new study. The landmark Women's Health Initiative study showed unequivocally that hormone therapy helps strengthen women's bones and prevents fractures of hip, wrist and spine by 27% to 35%. However, hormone use fell out of favor after studies in 2002 showed it raised the risk of breast cancer and did not lower heart-disease risk and, in fact, may elevate the risk in some women.
NEWS
April 6, 2011 | By Shari Roan, Los Angeles Times
Hormone therapy has been one of the most confusing issues in women's health over the last decade. Now, a study from the Women's Health Initiative shows the increased risk of stroke found among women who take estrogen-only hormone therapy disappears after they stop the pills but the reduced risk of breast cancer -- believed by some to result from hormone use after natural menopause -- is maintained. The findings should help women who have had a hysterectomy better weigh their risks and benefits of taking estrogen based on their age and symptoms.
HEALTH
April 5, 2011 | By Shari Roan, Los Angeles Times
Although many women have sworn off hormone therapy, a new analysis from the clinical trial that first unearthed the hormones' risks shows taking estrogen alone for menopausal symptoms, even for several years, may be safer than first thought. The new finding — the latest from the Women's Health Initiative, a federally funded trial that tracked thousands of women taking hormones or placebo pills for years — looked at women who have had hysterectomies and thus can take estrogen unaccompanied by another hormone, progestin.
SCIENCE
September 20, 2009 | Thomas H. Maugh II
Hormone replacement therapy, already linked to increased risk of breast cancer, heart disease and stroke, nearly doubles a woman's risk of dying from lung cancer, researchers reported Saturday in a finding that may be the final blow for a therapy that is already in rapidly declining use. The findings "seriously question whether hormone-replacement therapy has any role in medicine today," Dr. Apar Kishor Ganti of the University of Nebraska Medical...
NEWS
November 18, 2010 | By Shari Roan, Los Angeles Times
Hormone therapy appears to affect the brain differently depending on the age of the woman when she receives it, researchers reported Thursday. Hormone-replacement therapy for women has been the subject of considerable debate. Studies have shown both pros and cons. But hormone use has declined in the last decade because a major study on the issue, the Women's Health Initiative , found that the risks of taking hormones appeared to outweigh significantly the benefits in older postmenopausal women.
SCIENCE
July 18, 2013 | By Eryn Brown, This post has been updated. See below for details.
Hormone replacement therapy has plummeted among U.S. women since the Women's Health Initiative cut short its Estrogen Plus Progestin Trial in 2002, when study results revealed that women who took the two-hormone therapy suffered adverse effects and higher mortality. But the widespread rejection since of all hormone replacement therapies among menopausal women has been misguided, a team of researchers from the Yale School of Medicine in New Haven, Conn., wrote Thursday in the online edition of the American Journal of Public Health .  Looking at a separate group of women than those followed in the 2002 trial - women ages 50 to 59 who had had hysterectomies - Dr. Philip Sarrel and colleagues calculated that rejecting estrogen-only hormone therapy resulted in the early deaths of nearly 50,000 women between 2002 and 2011.
Los Angeles Times Articles
|